查看購物車
  • English
  • Japanese
  • Korean
封面
市場調查報告書
商品編碼
2158069

CRISPR市場：按產品、應用、最終用戶、競爭對手和地區分類－全球預測至2031年

CRISPR Market by Offering (Products [Kits, Enzymes, Libraries], Services [gRNA Synthesis, Cell Line Development, Screening, Validation]), Application (Drug Discovery, Development, Agriculture), End User, Competition, Region - Global Forecast to 2031
出版日期: | 出版商: MarketsandMarkets | 英文 319 Pages | 訂單完成後即時交付

價格

CRISPR 市場預計將從 2026 年的 34.8 億美元成長到 2031 年的 61.2 億美元，預測期內複合年成長率為 12.0%。

市場成長的驅動力是 CRISPR 基因組編輯技術在藥物發現、功能基因組學、細胞和基因治療、遺傳疾病研究和分子診斷等領域的日益普及。

調查範圍
調查期 2026-2031
基準年 2025
預測期 2026-2031
計算單位 金額（10億美元）
部分 產品/服務、產品類型、產品最終用戶、服務、服務最終用戶和應用
目標區域 北美洲、歐洲、亞太地區、拉丁美洲、中東和非洲

鹼基編輯、先導編輯、RNA編輯和高保真CRISPR系統的進步進一步擴展了基因組編輯的應用範圍。對高精度、可擴展且可重複的基因組編輯工作流程日益成長的需求也推動了CRISPR產品和服務的普及應用。

CRISPR市場-IMG1

“預計在預測期內，CRISPR試劑盒酶細分市場將以最高的複合年成長率成長。”

預計在預測期內，CRISPR試劑盒和酵素產品將以最高的複合年成長率成長，這主要得益於研發和基因組工程工作流程整體現成基因組編輯試劑和酵素的需求不斷成長。這些產品支援多種應用，例如基於嚮導RNA的編輯、基因敲除、基因活化、編輯檢驗以及先進基因組編輯系統的開發。高通量篩檢、功能基因組學和新一代編輯器的日益普及正在推動對專用CRISPR試劑盒和酶的需求。高保真核酸酶、鹼基編輯器、先導編輯器和其他預設計編輯系統的持續開發預計將進一步促進對先進CRISPR產品的需求。

“藥物發現和開發領域佔據最大的市場佔有率。”

藥物發現與開發領域佔據了CRISPR市場最大的佔有率，這主要得益於基因組編輯技術在標靶識別、標靶檢驗、疾病模型建構、功能基因體學和藥物篩檢等方面的廣泛應用。製藥和生物技術公司正日益利用基於CRISPR的基因敲除、活化、抑制和篩檢技術來闡明基因功能和疾病機制，並識別潛在的治療標靶。 CRISPR技術在細胞和基因治療開發以及精準醫療領域的應用不斷成長，進一步推動了對基因組編輯產品、篩檢平台及相關服務的需求。

“預計美國在預測期內將以最高的複合年成長率成長。”

由於美國擁有眾多領先的基因組編輯公司、先進的生物醫學研究基礎設施以及CRISPR技術在研究和治療應用中的高普及率，預計美國將成為CRISPR市場複合年成長率最高的國家。 CRISPR技術在藥物研發、功能基因組學、細胞和基因治療、遺傳疾病研究以及精準醫療等領域的廣泛應用正在推動市場成長。製藥公司、生技公司、學術機構和研究組織擴大採用CRISPR-Cas系統、鹼基編輯、先導編輯、引導RNA設計以及基因組編輯篩檢和檢驗等技術，進一步刺激了市場需求。

本報告所進行的主要訪談依下列類別分類：

  • 依受訪者統計：供給面下降70%，需求面下降30%
  • 按職位分類：經理 - 45%，首席主管和總監 - 30%，高階主管 - 25%
  • 區域細分：北美 -40%，歐洲 -25%，亞太地區 -25%，拉丁美洲 -5%，中東和非洲 -5%

調查範圍

本研究報告從以下幾個方面分析了 CRISPR 市場：產品和服務、產品類型（CRISPR 試劑盒和酶、CRISPR 文庫及其他產品）、產品最終用戶（製藥和生物技術公司、學術和研究機構及其他最終用戶）、服務類型（gRNA合成和細胞株開發、篩檢和驗證及其他服務）、服務最終用戶（製藥和生物技術公司、學術和研究機構及其他最終用戶）、應用領域（藥物發現和藥物開發、農業及其他應用）以及地區（北美、歐洲、亞太地區、拉丁美洲以及中東和非洲）。

本報告詳細介紹了影響CRISPR市場成長的關鍵因素，例如促進因素、阻礙因素、挑戰和機會。透過對主要產業參與者的全面分析，報告深入剖析了每家公司的業務概況、產品系列、關鍵策略、新產品發布、收購以及與CRISPR市場相關的最新發展。此外，報告也對CRISPR產業生態系統中新興的新創公司進行了競爭分析。

購買本報告的主要好處

本報告透過提供整體市場及其細分市場的收入預測，為市場領導者和新參與企業提供支援。它還有助於相關人員更深入了解競爭格局，有效地進行業務定位，並制定合適的打入市場策略。透過本報告，相關人員可以掌握市場趨勢，並獲取有關關鍵市場促進因素、限制因素、機會和挑戰的資訊。

本報告深入分析了以下幾點：

  • 分析影響市場成長的關鍵促進因素（對基於 CRISPR 的基因療法的需求不斷成長、CRISPR 技術的進步以及政府和私人對 CRISPR 技術的投資和資金籌措不斷增加）、阻礙因素（與 CRISPR 技術相關的技術挑戰）、機遇（開發針對遺傳疾病的新疫苗和療法，以及 CRISPR 技術相關的技術挑戰）、機遇（開發針對遺傳疾病的新疫苗和療法，以及 CRISPR 在工業和農業發展領域的發展障礙
  • 產品開發/創新：對 CRISPR 市場的新產品發布和創新進行詳細分析。
  • 市場開發：提供各地區盈利市場的全面資訊及市場分析。
  • 市場多元化：全面介紹 CRISPR 市場的新產品、未開發的市場、近期趨勢和投資情況。

目錄

第1章：引言

第2章執行摘要

第3章重要考察

  • CRISPR市場概覽
  • 北美 CRISPR 市場：按服務分類
  • CRISPR市場：區域成長機遇
  • CRISPR市場佔有率：依服務類型分類，2026年與2031年比較（%）

第4章 市場概覽

  • 市場動態
    • 促進因素
    • 抑制因子
    • 機會
    • 任務
  • 未滿足的需求和未開發的領域
  • 相互關聯的市場與跨產業機遇
  • 一級/二級/三級主要公司的策略性舉措

第5章 產業趨勢

  • 波特五力分析
    • 新進入者的威脅
    • 替代品的威脅
    • 買方的議價能力
    • 供應商的議價能力
    • 競爭公司之間的競爭
  • 宏觀經濟展望
    • GDP趨勢與預測
    • 全球醫療保健產業的趨勢
    • 全球生技產業的發展趨勢
  • 價值鏈分析
  • 生態系分析
    • 生態系中每位參與者的角色
  • 價格分析
    • 主要公司CRISPR試劑盒和試劑平均售價趨勢（2023-2025年）
    • CRISPR服務價格趨勢預測
    • 各地區 CRISPR 試劑盒及試劑的平均售價（2025 年）
  • 貿易分析
    • 進口方案（HS編碼3822.00）
    • 出口方案（HS編碼3822.00）
  • 2026-2027 年主要會議和活動
  • 影響客戶業務的趨勢和顛覆性因素
  • 投資和資金籌措場景
  • 案例研究分析
    • CRISPR-Cas9基因編輯技術展現出持續的降血脂效果。
    • 體內 CRISPR 編輯可顯著降低遺傳性血管性水腫發作的發生率。
  • 2025年美國關稅對CRISPR市場的影響
    • 主要關稅稅率
    • 價格影響分析
    • 對國家和地區的影響
    • 對終端用戶產業的影響

第6章：技術進步、人工智慧的影響、專利、創新與未來應用

  • 技術分析
    • 主要技術
    • 互補技術
    • 鄰近技術
  • 技術藍圖
  • 專利分析
    • 調查方法
    • 申請數量（按文件類型分類）
    • 主要專利列表
  • 未來用途
  • 人工智慧/通用人工智慧對CRISPR市場的影響
    • 主要應用場景和市場潛力
    • AI驅動的CRISPR工作流程的最佳實踐
    • CRISPR市場中人工智慧應用案例研究
    • 相互關聯的鄰近生態系及其對市場參與者的影響
    • 客戶對實施人工智慧整合CRISPR技術的準備情況

第7章永續性和監管情勢

  • 區域法規和合規性
    • 監管機構、政府機構和其他組織
    • 業界標準
  • 永續發展計劃
  • 監理政策對永續發展措施的影響
  • 認證、標籤和環境標準

第8章：顧客趨勢與購買行為

  • 決策流程
  • 買方相關人員和採購評估標準
    • 採購過程中的關鍵相關人員
    • CRISPR市場：購買標準
  • 實施障礙和內部挑戰
  • 各個終端用戶產業中尚未滿足的需求

第9章 CRISPR市場：透過提供

  • 產品
  • 服務

第10章：CRISPR產品市場：按類型分類

  • CRISPR試劑盒和酶
  • CRISPR 文庫
  • 其他產品

第11章：CRISPR產品市場：依最終用戶分類

  • 製藥和生物技術公司
  • 學術和研究機構
  • 其他最終用戶

第12章：CRISPR市場：依服務分類

  • 其他服務

第13章：CRISPR服務市場：依最終用戶分類

  • 製藥和生物技術公司
  • 學術和研究機構
  • 其他最終用戶

第14章 CRISPR市場：依應用領域分類

  • 藥物發現和藥物開發
  • 農業
  • 其他用途

第15章：CRISPR市場：按地區分類

  • 北美洲
    • 美國
    • 加拿大
  • 歐洲
    • 德國
    • 英國
    • 法國
    • 義大利
    • 西班牙
    • 其他歐洲國家
  • 亞太地區
    • 中國
    • 日本
    • 印度
    • 澳洲
    • 韓國
    • 亞太其他地區
  • 拉丁美洲
    • 巴西
    • 其他拉丁美洲
  • 中東
    • 海灣合作理事會國家
    • 其他中東國家
  • 非洲
    • 擴大農業生物技術和基因組學研究以推動市場發展。

第16章 競爭格局

  • 主要參與企業的策略/優勢，2023年1月至2026年9月
    • 2023年1月至2026年9月CRISPR市場主要參與者策略概述
  • 2021-2025年收入分析
  • 2025年市佔率分析
  • 企業估值矩陣：主要公司，2025 年
    • 明星公司
    • 新興領導者
    • 玩家種類繁多
    • 參與企業
    • 企業企業發展：主要公司，2025 年
  • 公司估值矩陣：新創企業/中小企業，2025 年
    • 先進公司
    • 應對力的公司
    • 充滿活力的公司
    • 起始點
    • 競爭標竿分析：新創企業/中小企業
  • 企業估值和財務指標
    • 企業估值和財務指標
    • 企業估值和財務指標
  • 品牌對比
  • 競爭格局
    • 新產品發布
    • 交易
    • 業務拓展

第17章：公司簡介

  • 大公司
    • THERMO FISHER SCIENTIFIC INC.
    • MERCK KGAA
    • AGILENT TECHNOLOGIES, INC.
    • GENSCRIPT
    • REVVITY
    • LONZA
    • DANAHER CORPORATION
    • TAKARA BIO INC.
    • CREATIVE BIOGENE
    • FUJIAN SUNYBIOTECH CO., LTD.
    • EDITCO
    • CARIBOU BIOSCIENCES, INC.
    • DEMEETRA AGBIO
    • ORIGENE TECHNOLOGIES, INC.
    • CELLECTA, INC.
  • 其他主要公司
    • MAMMOTH BIOSCIENCES, INC.
    • APPLIED STEMCELL
    • NEW ENGLAND BIOLABS
    • TOOLGEN, INC.
    • GENECOPOEIA, INC.
    • TWIST BIOSCIENCE
    • SYNTHEGO
    • EGENESIS
    • MANUS BIO
    • PRECISION BIOSCIENCES

第18章：調查方法

第19章附錄

Product Code: BT 6746

The CRISPR market is expected to reach USD 6.12 billion in 2031 from USD 3.48 billion in 2026, at a CAGR of 12.0% during the forecast period. Market growth is driven by the increasing adoption of CRISPR-based genome editing in drug discovery, functional genomics, cell and gene therapy, genetic disease research, and molecular diagnostics.

Scope of the Report
Years Considered for the Study2026-2031
Base Year2025
Forecast Period2026-2031
Units ConsideredValue (USD billion)
SegmentsOffering, Product Type, Product End User, Service, Service End User and Application
Regions coveredNorth America, Europe, Asia Pacific, Latin America, the Middle East, and Africa

Advancements in base editing, prime editing, RNA editing, and high-fidelity CRISPR systems are further expanding the range of genome-editing applications. Increasing demand for precise, scalable, and reproducible genome-editing workflows is also supporting the adoption of CRISPR products and services.

CRISPR Market - IMG1

"The CRISPR kits & enzymes segment is expected to grow at the highest CAGR during the forecast period"

The CRISPR kits & enzymes segment is expected to grow at the highest CAGR during the forecast period, driven by increasing demand for ready-to-use genome-editing reagents and enzymes across research and genome-engineering workflows. These products support applications such as guide RNA-based editing, gene knockout, gene activation, editing validation, and development of advanced genome-editing systems. Growing adoption of high-throughput screening, functional genomics, and next-generation editors is increasing the need for specialized CRISPR kits and enzymes. Continued development of high-fidelity nucleases, base editors, prime editors, and other engineered editing systems is expected to further support demand for advanced CRISPR products.

"The drug discovery & development segment holds the largest share of the market"

The drug discovery & development segment holds the largest share of the CRISPR market, supported by the increasing use of genome editing for target identification, target validation, disease-model development, functional genomics, and drug screening. Pharmaceutical and biotechnology companies increasingly use CRISPR-based knockout, activation, inhibition, and screening approaches to investigate gene function and disease mechanisms and identify potential therapeutic targets. The growing use of CRISPR in cell and gene therapy development and precision medicine is further supporting demand for genome-editing products, screening platforms, and related services.

"The US is expected to grow at the highest CAGR during the forecast period"

The US is expected to grow at the highest CAGR in the CRISPR market due to its strong presence of leading genome-editing companies, advanced biomedical research infrastructure, and high adoption of CRISPR technologies across research and therapeutic applications. Rising use of CRISPR in drug discovery, functional genomics, cell and gene therapy, genetic disease research, and precision medicine is driving market growth. Technologies such as CRISPR-Cas systems, base editing, prime editing, guide RNA design, and genome-editing screening and validation are increasingly used across pharmaceutical companies, biotechnology firms, academic institutes, and research organizations, further supporting demand.

The primary interviews conducted for this report can be categorized as follows:

  • By Respondent: Supply Side - 70% and Demand Side - 30%
  • By Designation: Managers - 45%, CXOs and Directors - 30%, and Executives - 25%
  • By Region: North America - 40%, Europe - 25%, Asia Pacific - 25%, Latin America - 5%, the Middle East & Africa - 5%

Thermo Fisher Scientific Inc. (US), Merck KGaA (Germany), Agilent Technologies, Inc. (US), GenScript (US), Takara Bio Inc. (Japan), Creative Biogene (US), Fujian SunvBiotech Co., Ltd. (China), EditCR (US), Caribou Biosciences, Inc. (US), Lonza (Switzerland), and Danaher Corporation (US) are some of the key companies offering CRISPR products and services.

Research Coverage

This research report categorizes the CRISPR market by offering (products and services), product type (CRISPR kits & enzymes, CRISPR libraries, and other products), product end user (pharmaceutical & biotechnology companies, academic & research institutes, and other end users), service type (gRNA synthesis & cell line development, screening & validation, and other services), service end user (pharmaceutical & biotechnology companies, academic & research institutes, and other end users), application (drug discovery & development, agriculture, and other applications), and region (North America, Europe, Asia Pacific, Latin America, and Middle East & Africa).

The report's scope encompasses detailed information about the primary factors, including drivers, restraints, challenges, and opportunities, that influence the growth of the CRISPR market. A comprehensive analysis of key industry players provides insights into their business overview, product portfolio, key strategies, new product launches, acquisitions, and recent developments related to the CRISPR market. This report also includes a competitive analysis of emerging startups in the CRISPR industry ecosystem.

Key Benefits of Buying the Report

The report will assist market leaders and new entrants by providing revenue estimates for the overall market and its subsegments. It will also help stakeholders better understand the competitive landscape and gain more insights to position their businesses effectively and develop suitable go-to-market strategies. This report will enable stakeholders to grasp the market's pulse and offer information on key market drivers, restraints, opportunities, and challenges.

The report provides insights into the following pointers:

  • Analysis of key drivers (growing demand for CRISPR-based gene therapies, advancements in CRISPR technology, growing government and private investments and funding for CRISPR technology), restraints (technical challenges associated with CRISPR technology), opportunities (development of new vaccines and treatments for genetic diseases, expanding industrial and agricultural applications of CRISPR), and challenges (regulatory hurdles for CRISPR advancements) influencing the market growth
  • Product Development/Innovation: Detailed insights into newly launched products and innovations in the CRISPR market
  • Market Development: Comprehensive information about lucrative markets and analysis of the market across varied regions
  • Market Diversification: Exhaustive information about new products, untapped geographies, recent developments, and investments in the CRISPR market
  • Competitive Assessment: In-depth assessment of market shares, growth strategies, and products of leading players, Thermo Fisher Scientific Inc. (US), Merck KGaA (Germany), Agilent Technologies, Inc. (US), GenScript (US), Takara Bio (Japan), Revvity (US), Danaher (US), and Lonza (Switzerland), among others, for the CRISPR market

TABLE OF CONTENTS

1 INTRODUCTION

  • 1.1 STUDY OBJECTIVES
  • 1.2 MARKET DEFINITION
  • 1.3 STUDY SCOPE
    • 1.3.1 MARKETS COVERED & REGIONAL SCOPE
    • 1.3.2 INCLUSIONS & EXCLUSIONS
    • 1.3.3 YEARS CONSIDERED
    • 1.3.4 CURRENCY CONSIDERED
  • 1.4 STAKEHOLDERS
  • 1.5 SUMMARY OF CHANGES

2 EXECUTIVE SUMMARY

  • 2.1 MARKET HIGHLIGHTS & KEY INSIGHTS
  • 2.2 KEY MARKET PARTICIPANTS: MAPPING OF STRATEGIC DEVELOPMENTS
  • 2.3 DISRUPTIVE TRENDS IN CRISPR MARKET
  • 2.4 HIGH-GROWTH SEGMENTS
  • 2.5 REGIONAL SNAPSHOT: MARKET SIZE, GROWTH RATE, AND FORECAST

3 PREMIUM INSIGHTS

  • 3.1 CRISPR MARKET OVERVIEW
  • 3.2 NORTH AMERICA: CRISPR MARKET, BY SERVICE
  • 3.3 CRISPR MARKET: GEOGRAPHIC GROWTH OPPORTUNITIES
  • 3.4 CRISPR MARKET SHARE, BY OFFERING, 2026 VS. 2031 (%)

4 MARKET OVERVIEW

  • 4.1 INTRODUCTION
  • 4.2 MARKET DYNAMICS
    • 4.2.1 DRIVERS
      • 4.2.1.1 Growing demand for CRISPR-based gene therapies
      • 4.2.1.2 Advancements in CRISPR technology
      • 4.2.1.3 Growing government and private investments and funding for CRISPR technology
    • 4.2.2 RESTRAINTS
      • 4.2.2.1 Technical challenges associated with CRISPR technology
    • 4.2.3 OPPORTUNITIES
      • 4.2.3.1 Development of new vaccines and treatments for genetic diseases
      • 4.2.3.2 Expanding industrial and agricultural applications of CRISPR
    • 4.2.4 CHALLENGES
      • 4.2.4.1 Regulatory hurdles for CRISPR advancements
  • 4.3 UNMET NEEDS & WHITE SPACES
  • 4.4 INTERCONNECTED MARKETS & CROSS-SECTOR OPPORTUNITIES
  • 4.5 STRATEGIC MOVES BY TIER-1/2/3 PLAYERS

5 INDUSTRY TRENDS

  • 5.1 PORTER'S FIVE FORCES ANALYSIS
    • 5.1.1 THREAT OF NEW ENTRANTS
    • 5.1.2 THREAT OF SUBSTITUTES
    • 5.1.3 BARGAINING POWER OF BUYERS
    • 5.1.4 BARGAINING POWER OF SUPPLIERS
    • 5.1.5 INTENSITY OF COMPETITIVE RIVALRY
  • 5.2 MACROECONOMIC OUTLOOK
    • 5.2.1 INTRODUCTION
    • 5.2.2 GDP TRENDS & FORECAST
    • 5.2.3 TRENDS IN GLOBAL HEALTHCARE INDUSTRY
    • 5.2.4 TRENDS IN GLOBAL BIOTECH INDUSTRY
  • 5.3 VALUE CHAIN ANALYSIS
  • 5.4 ECOSYSTEM ANALYSIS
    • 5.4.1 ROLE OF PLAYERS IN ECOSYSTEM
  • 5.5 PRICING ANALYSIS
    • 5.5.1 AVERAGE SELLING PRICE TREND OF CRISPR KITS & REAGENTS, BY KEY PLAYER, 2023-2025
    • 5.5.2 INDICATIVE PRICE TREND FOR CRISPR SERVICES
    • 5.5.3 AVERAGE SELLING PRICE OF CRISPR KITS & REAGENTS, BY REGION, 2025
  • 5.6 TRADE ANALYSIS
    • 5.6.1 IMPORT SCENARIO (HS CODE 3822.00)
    • 5.6.2 EXPORT SCENARIO (HS CODE 3822.00)
  • 5.7 KEY CONFERENCES & EVENTS, 2026-2027
  • 5.8 TRENDS/DISRUPTIONS IMPACTING CUSTOMERS' BUSINESSES
  • 5.9 INVESTMENT & FUNDING SCENARIO
  • 5.10 CASE STUDY ANALYSIS
    • 5.10.1 CRISPR-CAS9 EDITING DEMONSTRATES DURABLE LIPID REDUCTION
    • 5.10.2 IN VIVO CRISPR EDITING SIGNIFICANTLY REDUCES HEREDITARY ANGIOEDEMA ATTACKS
  • 5.11 IMPACT OF 2025 US TARIFFS ON CRISPR MARKET
    • 5.11.1 INTRODUCTION
    • 5.11.2 KEY TARIFF RATES
    • 5.11.3 PRICE IMPACT ANALYSIS
    • 5.11.4 IMPACT ON COUNTRY/REGION
      • 5.11.4.1 US
      • 5.11.4.2 Europe
      • 5.11.4.3 Asia Pacific
      • 5.11.4.4 Rest of the World
    • 5.11.5 IMPACT ON END-USE INDUSTRIES
      • 5.11.5.1 Pharmaceutical & biotech companies
      • 5.11.5.2 Contract Research Organizations (CROs)
      • 5.11.5.3 Academic & research institutes

6 TECHNOLOGICAL ADVANCEMENTS, AI-DRIVEN IMPACT, PATENTS, INNOVATIONS, AND FUTURE APPLICATIONS

  • 6.1 TECHNOLOGY ANALYSIS
    • 6.1.1 KEY TECHNOLOGIES
      • 6.1.1.1 CRISPR-Cas systems
      • 6.1.1.2 gRNA design & optimization
      • 6.1.1.3 High-throughput CRISPR screening
    • 6.1.2 COMPLEMENTARY TECHNOLOGIES
      • 6.1.2.1 Synthetic biology
      • 6.1.2.2 Single-cell genomics
      • 6.1.2.3 Next-generation sequencing
    • 6.1.3 ADJACENT TECHNOLOGIES
      • 6.1.3.1 Stem cell engineering
      • 6.1.3.2 Synthetic DNA & gene synthesis
      • 6.1.3.3 Microfluidics
  • 6.2 TECHNOLOGY ROADMAP
  • 6.3 PATENT ANALYSIS
    • 6.3.1 METHODOLOGY
    • 6.3.2 NUMBER OF PATENTS FILED, BY DOCUMENT TYPE
    • 6.3.3 LIST OF KEY PATENTS
  • 6.4 FUTURE APPLICATIONS
  • 6.5 IMPACT OF AI/GEN AI ON CRISPR MARKET
    • 6.5.1 TOP USE CASES & MARKET POTENTIAL
    • 6.5.2 BEST PRACTICES IN AI-ENABLED CRISPR WORKFLOWS
    • 6.5.3 CASE STUDIES OF AI IMPLEMENTATION IN CRISPR MARKET
    • 6.5.4 INTERCONNECTED ADJACENT ECOSYSTEM & IMPACT ON MARKET PLAYERS
    • 6.5.5 CLIENTS' READINESS TO ADOPT AI-INTEGRATED CRISPR TECHNOLOGIES

7 SUSTAINABILITY & REGULATORY LANDSCAPE

  • 7.1 REGIONAL REGULATIONS & COMPLIANCE
    • 7.1.1 REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS
    • 7.1.2 INDUSTRY STANDARDS
      • 7.1.2.1 North America
        • 7.1.2.1.1 US
        • 7.1.2.1.2 Canada
      • 7.1.2.2 Europe
        • 7.1.2.2.1 Germany
        • 7.1.2.2.2 UK
        • 7.1.2.2.3 France
      • 7.1.2.3 Asia Pacific
        • 7.1.2.3.1 Japan
        • 7.1.2.3.2 China
      • 7.1.2.4 Latin America
        • 7.1.2.4.1 Brazil
      • 7.1.2.5 Middle East & Africa
        • 7.1.2.5.1 GCC Countries
        • 7.1.2.5.2 South Africa
  • 7.2 SUSTAINABILITY INITIATIVES
  • 7.3 IMPACT OF REGULATORY POLICIES ON SUSTAINABILITY INITIATIVES
  • 7.4 CERTIFICATIONS, LABELING, AND ECO-STANDARDS

8 CUSTOMER LANDSCAPE & BUYER BEHAVIOR

  • 8.1 DECISION-MAKING PROCESS
  • 8.2 BUYER STAKEHOLDERS & BUYING EVALUATION CRITERIA
    • 8.2.1 KEY STAKEHOLDERS IN BUYING PROCESS
    • 8.2.2 CRISPR MARKET: BUYING CRITERIA
  • 8.3 ADOPTION BARRIERS & INTERNAL CHALLENGES
  • 8.4 UNMET NEEDS FROM VARIOUS END-USE INDUSTRIES

9 CRISPR MARKET, BY OFFERING

  • 9.1 INTRODUCTION
  • 9.2 PRODUCTS
    • 9.2.1 ADVANCEMENTS IN GENOME EDITING TO DRIVE GROWTH
  • 9.3 SERVICES
    • 9.3.1 GROWING DEMAND FOR PRECISE GENOME EDITING TOOLS IN RESEARCH AND CLINICAL APPLICATIONS TO BOOST MARKET

10 CRISPR PRODUCTS MARKET, BY TYPE

  • 10.1 INTRODUCTION
  • 10.2 CRISPR KITS & ENZYMES
    • 10.2.1 CRISPR KITS & ENZYMES SEGMENT TO DOMINATE CRISPR PRODUCTS MARKET DURING FORECAST PERIOD
  • 10.3 CRISPR LIBRARIES
    • 10.3.1 INCREASING APPLICATIONS OF CRISPR LIBRARIES IN GENE EDITING TO DRIVE GROWTH
  • 10.4 OTHER PRODUCTS

11 CRISPR PRODUCTS MARKET, BY END USER

  • 11.1 INTRODUCTION
  • 11.2 PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES
    • 11.2.1 INCREASING PRODUCT APPROVALS AND ROBUST CLINICAL PIPELINE TO PROPEL MARKET
  • 11.3 ACADEMIC & RESEARCH INSTITUTES
    • 11.3.1 INCREASING FUNDING FOR GENOMIC PROJECTS TO PROPEL MARKET
  • 11.4 OTHER END USERS

12 CRISPR MARKET, BY SERVICE

  • 12.1 INTRODUCTION
    • 12.1.1 GRNA SYNTHESIS & CELL LINE DEVELOPMENT
      • 12.1.1.1 Emerging opportunities in CRISPR gRNA synthesis & cell line development to drive growth
    • 12.1.2 SCREENING & VALIDATION
      • 12.1.2.1 Rapid advancements in CRISPR technology to drive growth
  • 12.2 OTHER SERVICES

13 CRISPR SERVICES MARKET, BY END USER

  • 13.1 INTRODUCTION
  • 13.2 PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES
    • 13.2.1 ADVANCEMENTS IN GENOME EDITING TO DRIVE GROWTH
  • 13.3 ACADEMIC & RESEARCH INSTITUTES
    • 13.3.1 INCREASING INVESTMENTS IN GENOMIC PROJECTS TO PROPEL MARKET
  • 13.4 OTHER END USERS

14 CRISPR MARKET, BY APPLICATION

  • 14.1 INTRODUCTION
  • 14.2 DRUG DISCOVERY & DEVELOPMENT
    • 14.2.1 ADVANCEMENTS IN GENOME EDITING TO DRIVE GROWTH
  • 14.3 AGRICULTURE
    • 14.3.1 GROWING DEMAND FOR ENHANCED CROP TRAITS TO DRIVE GROWTH
  • 14.4 OTHER APPLICATIONS

15 CRISPR MARKET, BY REGION

  • 15.1 INTRODUCTION
  • 15.2 NORTH AMERICA
    • 15.2.1 US
      • 15.2.1.1 Increasing demand for CRISPR products and services across various industries to drive growth
    • 15.2.2 CANADA
      • 15.2.2.1 Increasing demand for gene-editing technologies to boost growth
  • 15.3 EUROPE
    • 15.3.1 GERMANY
      • 15.3.1.1 Rapidly increasing biotechnology sector to support growth
    • 15.3.2 UK
      • 15.3.2.1 Significant government investments in genomics research to propel growth
    • 15.3.3 FRANCE
      • 15.3.3.1 Increasing demand for targeted therapies and personalized medicine to propel growth
    • 15.3.4 ITALY
      • 15.3.4.1 Increasing demand for innovative therapeutic solutions to drive growth
    • 15.3.5 SPAIN
      • 15.3.5.1 Increasing demand for precision medicine to drive growth
    • 15.3.6 REST OF EUROPE
  • 15.4 ASIA PACIFIC
    • 15.4.1 CHINA
      • 15.4.1.1 Increasing investments in R&D to drive growth
    • 15.4.2 JAPAN
      • 15.4.2.1 Potential of CRISPR-based therapies in personalized medicine to present opportunities for market growth
    • 15.4.3 INDIA
      • 15.4.3.1 Increasing prevalence of genetic disorders to support growth
    • 15.4.4 AUSTRALIA
      • 15.4.4.1 Growing clinical translation and advancements in CRISPR technologies to support growth
    • 15.4.5 SOUTH KOREA
      • 15.4.5.1 Advancements in next-generation CRISPR and precision RNA editing to support growth
    • 15.4.6 REST OF ASIA PACIFIC
  • 15.5 LATIN AMERICA
    • 15.5.1 BRAZIL
      • 15.5.1.1 Growing adoption of genome technologies to propel growth
    • 15.5.2 REST OF LATIN AMERICA
  • 15.6 MIDDLE EAST
    • 15.6.1 GCC COUNTRIES
      • 15.6.1.1 Saudi Arabia
        • 15.6.1.1.1 Regulatory support and expanding advanced-therapy infrastructure to boost market
      • 15.6.1.2 UAE
        • 15.6.1.2.1 Precision medicine investment and advanced clinical infrastructure to aid market growth
      • 15.6.1.3 Rest of GCC Countries
    • 15.6.2 REST OF MIDDLE EAST
  • 15.7 AFRICA
    • 15.7.1 EXPANDING AGRICULTURAL BIOTECHNOLOGY AND GENOMICS RESEARCH TO PROPEL MARKET

16 COMPETITIVE LANDSCAPE

  • 16.1 INTRODUCTION
  • 16.2 KEY PLAYER STRATEGY/RIGHT TO WIN, JANUARY 2023-SEPTEMBER 2026
    • 16.2.1 OVERVIEW OF STRATEGIES ADOPTED BY KEY PLAYERS IN CRISPR MARKET, JANUARY 2023-SEPTEMBER 2026
  • 16.3 REVENUE ANALYSIS, 2021-2025
  • 16.4 MARKET SHARE ANALYSIS, 2025
  • 16.5 COMPANY EVALUATION MATRIX: KEY PLAYERS, 2025
    • 16.5.1 STARS
    • 16.5.2 EMERGING LEADERS
    • 16.5.3 PERVASIVE PLAYERS
    • 16.5.4 PARTICIPANTS
    • 16.5.5 COMPANY FOOTPRINT: KEY PLAYERS, 2025
      • 16.5.5.1 Company footprint
      • 16.5.5.2 Region footprint
      • 16.5.5.3 Product footprint
      • 16.5.5.4 Service footprint
      • 16.5.5.5 Application footprint
  • 16.6 COMPANY EVALUATION MATRIX: STARTUPS/SMES, 2025
    • 16.6.1 PROGRESSIVE COMPANIES
    • 16.6.2 RESPONSIVE COMPANIES
    • 16.6.3 DYNAMIC COMPANIES
    • 16.6.4 STARTING BLOCKS
    • 16.6.5 COMPETITIVE BENCHMARKING: STARTUPS/SMES
      • 16.6.5.1 Detailed list of key startups/SMEs
      • 16.6.5.2 Competitive benchmarking of key startups/SMEs
  • 16.7 COMPANY VALUATION & FINANCIAL METRICS
    • 16.7.1 COMPANY VALUATION & FINANCIAL METRICS
    • 16.7.2 COMPANY VALUATION & FINANCIAL METRICS
  • 16.8 BRAND COMPARISON
  • 16.9 COMPETITIVE SCENARIO
    • 16.9.1 PRODUCT LAUNCHES
    • 16.9.2 DEALS
    • 16.9.3 EXPANSIONS

17 COMPANY PROFILES

  • 17.1 KEY PLAYERS
    • 17.1.1 THERMO FISHER SCIENTIFIC INC.
      • 17.1.1.1 Business overview
      • 17.1.1.2 Products & services offered
      • 17.1.1.3 Recent developments
        • 17.1.1.3.1 Expansions
      • 17.1.1.4 MnM view
        • 17.1.1.4.1 Key strengths
        • 17.1.1.4.2 Strategic choices
        • 17.1.1.4.3 Weaknesses & competitive threats
    • 17.1.2 MERCK KGAA
      • 17.1.2.1 Business overview
      • 17.1.2.2 Products & services offered
      • 17.1.2.3 Recent developments
        • 17.1.2.3.1 Product launches
        • 17.1.2.3.2 Deals
      • 17.1.2.4 MnM view
        • 17.1.2.4.1 Key strengths
        • 17.1.2.4.2 Strategic choices
        • 17.1.2.4.3 Weaknesses & competitive threats
    • 17.1.3 AGILENT TECHNOLOGIES, INC.
      • 17.1.3.1 Business overview
      • 17.1.3.2 Products & services offered
      • 17.1.3.3 Recent developments
        • 17.1.3.3.1 Deals
        • 17.1.3.3.2 Expansions
      • 17.1.3.4 MnM view
        • 17.1.3.4.1 Key strengths
        • 17.1.3.4.2 Strategic choices
        • 17.1.3.4.3 Weaknesses & competitive threats
    • 17.1.4 GENSCRIPT
      • 17.1.4.1 Business overview
      • 17.1.4.2 Products & services offered
      • 17.1.4.3 Recent developments
        • 17.1.4.3.1 Deals
        • 17.1.4.3.2 Expansions
      • 17.1.4.4 MnM view
        • 17.1.4.4.1 Key strengths
        • 17.1.4.4.2 Strategic choices
        • 17.1.4.4.3 Weaknesses & competitive threats
    • 17.1.5 REVVITY
      • 17.1.5.1 Business overview
      • 17.1.5.2 Products & services offered
      • 17.1.5.3 Recent developments
        • 17.1.5.3.1 Product launches
        • 17.1.5.3.2 Deals
    • 17.1.6 LONZA
      • 17.1.6.1 Business overview
      • 17.1.6.2 Products & services offered
      • 17.1.6.3 Recent developments
        • 17.1.6.3.1 Product launches
        • 17.1.6.3.2 Deals
        • 17.1.6.3.3 Expansions
    • 17.1.7 DANAHER CORPORATION
      • 17.1.7.1 Business overview
      • 17.1.7.2 Products & services offered
      • 17.1.7.3 Recent developments
        • 17.1.7.3.1 Product launches
        • 17.1.7.3.2 Deals
    • 17.1.8 TAKARA BIO INC.
      • 17.1.8.1 Business overview
      • 17.1.8.2 Products & services offered
      • 17.1.8.3 Recent developments
        • 17.1.8.3.1 Deals
    • 17.1.9 CREATIVE BIOGENE
      • 17.1.9.1 Business overview
      • 17.1.9.2 Products & services offered
      • 17.1.9.3 Recent developments
        • 17.1.9.3.1 Service launches
    • 17.1.10 FUJIAN SUNYBIOTECH CO., LTD.
      • 17.1.10.1 Business overview
      • 17.1.10.2 Products & services offered
    • 17.1.11 EDITCO
      • 17.1.11.1 Business overview
      • 17.1.11.2 Products & services offered
      • 17.1.11.3 Recent financials
        • 17.1.11.3.1 Deals
    • 17.1.12 CARIBOU BIOSCIENCES, INC.
      • 17.1.12.1 Business overview
      • 17.1.12.2 Products & services offered
      • 17.1.12.3 Recent developments
        • 17.1.12.3.1 Deals
    • 17.1.13 DEMEETRA AGBIO
      • 17.1.13.1 Business overview
      • 17.1.13.2 Products & services offered
      • 17.1.13.3 Recent developments
        • 17.1.13.3.1 Deals
    • 17.1.14 ORIGENE TECHNOLOGIES, INC.
      • 17.1.14.1 Business overview
      • 17.1.14.2 Products & services offered
    • 17.1.15 CELLECTA, INC.
      • 17.1.15.1 Business overview
      • 17.1.15.2 Products & services offered
  • 17.2 OTHER PLAYERS
    • 17.2.1 MAMMOTH BIOSCIENCES, INC.
    • 17.2.2 APPLIED STEMCELL
    • 17.2.3 NEW ENGLAND BIOLABS
    • 17.2.4 TOOLGEN, INC.
    • 17.2.5 GENECOPOEIA, INC.
    • 17.2.6 TWIST BIOSCIENCE
    • 17.2.7 SYNTHEGO
    • 17.2.8 EGENESIS
    • 17.2.9 MANUS BIO
    • 17.2.10 PRECISION BIOSCIENCES

18 RESEARCH METHODOLOGY

  • 18.1 RESEARCH DATA
    • 18.1.1 SECONDARY DATA
    • 18.1.2 PRIMARY RESEARCH
  • 18.2 MARKET SIZE ESTIMATION
    • 18.2.1 GLOBAL MARKET ESTIMATION
      • 18.2.1.1 Insights from primary experts
    • 18.2.2 SEGMENTAL MARKET ESTIMATION (TOP-DOWN APPROACH)
  • 18.3 MARKET GROWTH RATE PROJECTION
  • 18.4 DATA TRIANGULATION
  • 18.5 RESEARCH ASSUMPTIONS
  • 18.6 RESEARCH LIMITATIONS
  • 18.7 RISK ANALYSIS

19 APPENDIX

  • 19.1 DISCUSSION GUIDE
  • 19.2 KNOWLEDGESTORE: MARKETSANDMARKETS' SUBSCRIPTION PORTAL
  • 19.3 CUSTOMIZATION OPTIONS
  • 19.4 RELATED REPORTS
  • 19.5 AUTHOR DETAILS

List of Tables

  • TABLE 1 CRISPR MARKET: IMPACT ANALYSIS
  • TABLE 2 CRISPR MARKET: PORTER'S FIVE FORCES ANALYSIS
  • TABLE 3 CRISPR MARKET: ROLE OF PLAYERS IN ECOSYSTEM
  • TABLE 4 AVERAGE SELLING PRICE TREND OF CRISPR KITS & REAGENTS, BY KEY PLAYER, 2023-2025
  • TABLE 5 AVERAGE SELLING PRICE OF CRISPR KITS & REAGENTS, BY REGION, 2025 (USD)
  • TABLE 6 IMPORT DATA FOR HS CODE 3822.00-COMPLIANT PRODUCTS, BY COUNTRY, 2021-2025 (USD THOUSAND)
  • TABLE 7 EXPORT DATA FOR HS CODE 3822.00-COMPLIANT PRODUCTS, BY COUNTRY, 2021-2025 (USD THOUSAND)
  • TABLE 8 CRISPR MARKET: KEY CONFERENCES & EVENTS, 2026-2027
  • TABLE 9 RECIPROCAL TARIFF RATES ADJUSTED BY US
  • TABLE 10 KEY TARIFFS ON PHARMACEUTICAL PRODUCTS
  • TABLE 11 CRITICAL COMPONENTS LIKELY EXPOSED TO TARIFF CHANGES
  • TABLE 12 NUMBER OF PATENTS FILED, BY DOCUMENT TYPE, 2015-2025
  • TABLE 13 LIST OF KEY PATENTS IN CRISPR MARKET, 2023-2025
  • TABLE 14 CASE STUDIES OF AI IMPLEMENTATION IN CRISPR MARKET
  • TABLE 15 CLIENTS' READINESS TO ADOPT AI-INTEGRATED CRISPR TECHNOLOGIES
  • TABLE 16 NORTH AMERICA: REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS
  • TABLE 17 EUROPE: REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS
  • TABLE 18 ASIA PACIFIC: REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS
  • TABLE 19 LATIN AMERICA: REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS
  • TABLE 20 MIDDLE EAST & AFRICA: REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS
  • TABLE 21 INFLUENCE OF KEY STAKEHOLDERS ON BUYING PROCESS, BY OFFERING
  • TABLE 22 KEY BUYING CRITERIA, BY END USER (PRODUCTS)
  • TABLE 23 KEY BUYING CRITERIA, BY END USER (SERVICES)
  • TABLE 24 CRISPR MARKET, BY OFFERING, 2023-2031 (USD MILLION)
  • TABLE 25 CRISPR PRODUCTS MARKET, BY REGION, 2023-2031 (USD MILLION)
  • TABLE 26 NORTH AMERICA: CRISPR PRODUCTS MARKET, BY COUNTRY, 2023-2031 (USD MILLION)
  • TABLE 27 EUROPE: CRISPR PRODUCTS MARKET, BY COUNTRY, 2023-2031 (USD MILLION)
  • TABLE 28 ASIA PACIFIC: CRISPR PRODUCTS MARKET, BY COUNTRY, 2023-2031 (USD MILLION)
  • TABLE 29 LATIN AMERICA: CRISPR PRODUCTS MARKET, BY COUNTRY, 2023-2031 (USD MILLION)
  • TABLE 30 MIDDLE EAST: CRISPR PRODUCTS MARKET, BY REGION, 2023-2031 (USD MILLION)
  • TABLE 31 GCC COUNTRIES: CRISPR PRODUCTS MARKET, BY COUNTRY, 2023-2031 (USD MILLION)
  • TABLE 32 CRISPR SERVICES MARKET, BY REGION, 2023-2031 (USD MILLION)
  • TABLE 33 NORTH AMERICA: CRISPR SERVICES MARKET, BY COUNTRY, 2023-2031 (USD MILLION)
  • TABLE 34 EUROPE: CRISPR SERVICES MARKET, BY COUNTRY, 2023-2031 (USD MILLION)
  • TABLE 35 ASIA PACIFIC: CRISPR SERVICES MARKET, BY COUNTRY, 2023-2031 (USD MILLION)
  • TABLE 36 LATIN AMERICA: CRISPR SERVICES MARKET, BY COUNTRY, 2023-2031 (USD MILLION)
  • TABLE 37 MIDDLE EAST: CRISPR SERVICES MARKET, BY REGION, 2023-2031 (USD MILLION)
  • TABLE 38 GCC COUNTRIES: CRISPR SERVICES MARKET, BY COUNTRY, 2023-2031 (USD MILLION)
  • TABLE 39 CRISPR PRODUCTS MARKET, BY TYPE, 2023-2031 (USD MILLION)
  • TABLE 40 CRISPR KITS & ENZYMES MARKET, BY REGION, 2023-2031 (USD MILLION)
  • TABLE 41 NORTH AMERICA: CRISPR KITS & ENZYMES MARKET, BY COUNTRY, 2023-2031 (USD MILLION)
  • TABLE 42 EUROPE: CRISPR KITS & ENZYMES MARKET, BY COUNTRY, 2023-2031 (USD MILLION)
  • TABLE 43 ASIA PACIFIC: CRISPR KITS & ENZYMES MARKET, BY COUNTRY, 2023-2031 (USD MILLION)
  • TABLE 44 LATIN AMERICA: CRISPR KITS & ENZYMES MARKET, BY COUNTRY, 2023-2031 (USD MILLION)
  • TABLE 45 MIDDLE EAST: CRISPR KITS & ENZYMES MARKET, BY REGION, 2023-2031 (USD MILLION)
  • TABLE 46 GCC COUNTRIES: CRISPR KITS & ENZYMES MARKET, BY COUNTRY, 2023-2031 (USD MILLION)
  • TABLE 47 CRISPR LIBRARIES MARKET, BY REGION, 2023-2031 (USD MILLION)
  • TABLE 48 NORTH AMERICA: CRISPR LIBRARIES MARKET, BY COUNTRY, 2023-2031 (USD MILLION)
  • TABLE 49 EUROPE: CRISPR LIBRARIES MARKET, BY COUNTRY, 2023-2031 (USD MILLION)
  • TABLE 50 ASIA PACIFIC: CRISPR LIBRARIES MARKET, BY COUNTRY, 2023-2031 (USD MILLION)
  • TABLE 51 LATIN AMERICA: CRISPR LIBRARIES MARKET, BY COUNTRY, 2023-2031 (USD MILLION)
  • TABLE 52 MIDDLE EAST: CRISPR LIBRARIES MARKET, BY REGION, 2023-2031 (USD MILLION)
  • TABLE 53 GCC COUNTRIES: CRISPR LIBRARIES MARKET, BY COUNTRY, 2023-2031 (USD MILLION)
  • TABLE 54 OTHER CRISPR PRODUCTS MARKET, BY REGION, 2023-2031 (USD MILLION)
  • TABLE 55 NORTH AMERICA: OTHER CRISPR PRODUCTS MARKET, BY COUNTRY, 2023-2031 (USD MILLION)
  • TABLE 56 EUROPE: OTHER CRISPR PRODUCTS MARKET, BY COUNTRY, 2023-2031 (USD MILLION)
  • TABLE 57 ASIA PACIFIC: OTHER CRISPR PRODUCTS MARKET, BY COUNTRY, 2023-2031 (USD MILLION)
  • TABLE 58 LATIN AMERICA: OTHER CRISPR PRODUCTS MARKET, BY COUNTRY, 2023-2031 (USD MILLION)
  • TABLE 59 MIDDLE EAST: OTHER CRISPR PRODUCTS MARKET, BY REGION, 2023-2031 (USD MILLION)
  • TABLE 60 GCC COUNTRIES: OTHER CRISPR PRODUCTS MARKET, BY COUNTRY, 2023-2031 (USD MILLION)
  • TABLE 61 CRISPR PRODUCTS MARKET, BY END USER, 2023-2031 (USD MILLION)
  • TABLE 62 CRISPR PRODUCTS MARKET FOR PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES, BY REGION, 2023-2031 (USD MILLION)
  • TABLE 63 NORTH AMERICA: CRISPR PRODUCTS MARKET FOR PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES, BY COUNTRY, 2023-2031 (USD MILLION)
  • TABLE 64 EUROPE: CRISPR PRODUCTS MARKET FOR PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES, BY COUNTRY, 2023-2031 (USD MILLION)
  • TABLE 65 ASIA PACIFIC: CRISPR PRODUCTS MARKET FOR PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES, BY COUNTRY, 2023-2031 (USD MILLION)
  • TABLE 66 LATIN AMERICA: CRISPR PRODUCTS MARKET FOR PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES, BY COUNTRY, 2023-2031 (USD MILLION)
  • TABLE 67 MIDDLE EAST: CRISPR PRODUCTS MARKET FOR PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES, BY REGION, 2023-2031 (USD MILLION)
  • TABLE 68 GCC COUNTRIES: CRISPR PRODUCTS MARKET FOR PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES, BY COUNTRY, 2023-2031 (USD MILLION)
  • TABLE 69 CRISPR PRODUCTS MARKET FOR ACADEMIC & RESEARCH INSTITUTES, BY REGION, 2023-2031 (USD MILLION)
  • TABLE 70 NORTH AMERICA: CRISPR PRODUCTS MARKET FOR ACADEMIC & RESEARCH INSTITUTES, BY COUNTRY, 2023-2031 (USD MILLION)
  • TABLE 71 EUROPE: CRISPR PRODUCTS MARKET FOR ACADEMIC & RESEARCH INSTITUTES, BY COUNTRY, 2023-2031 (USD MILLION)
  • TABLE 72 ASIA PACIFIC: CRISPR PRODUCTS MARKET FOR ACADEMIC & RESEARCH INSTITUTES, BY COUNTRY, 2023-2031 (USD MILLION)
  • TABLE 73 LATIN AMERICA: CRISPR PRODUCTS MARKET FOR ACADEMIC & RESEARCH INSTITUTES, BY COUNTRY, 2023-2031 (USD MILLION)
  • TABLE 74 MIDDLE EAST: CRISPR PRODUCTS MARKET FOR ACADEMIC & RESEARCH INSTITUTES, BY REGION, 2023-2031 (USD MILLION)
  • TABLE 75 GCC COUNTRIES: CRISPR PRODUCTS MARKET FOR ACADEMIC & RESEARCH INSTITUTES, BY COUNTRY, 2023-2031 (USD MILLION)
  • TABLE 76 CRISPR PRODUCTS MARKET FOR OTHER END USERS, BY REGION, 2023-2031 (USD MILLION)
  • TABLE 77 NORTH AMERICA: CRISPR PRODUCTS MARKET FOR OTHER END USERS, BY COUNTRY, 2023-2031 (USD MILLION)
  • TABLE 78 EUROPE: CRISPR PRODUCTS MARKET FOR OTHER END USERS, BY COUNTRY, 2023-2031 (USD MILLION)
  • TABLE 79 ASIA PACIFIC: CRISPR PRODUCTS MARKET FOR OTHER END USERS, BY COUNTRY, 2023-2031 (USD MILLION)
  • TABLE 80 LATIN AMERICA: CRISPR PRODUCTS MARKET FOR OTHER END USERS, BY COUNTRY, 2023-2031 (USD MILLION)
  • TABLE 81 MIDDLE EAST: CRISPR PRODUCTS MARKET FOR OTHER END USERS, BY REGION, 2023-2031 (USD MILLION)
  • TABLE 82 GCC COUNTRIES: CRISPR PRODUCTS MARKET FOR OTHER END USERS, BY COUNTRY, 2023-2031 (USD MILLION)
  • TABLE 83 CRISPR MARKET, BY SERVICE, 2023-2031 (USD MILLION)
  • TABLE 84 CRISPR SERVICES MARKET FOR GRNA SYNTHESIS & CELL LINE DEVELOPMENT, BY REGION, 2023-2031 (USD MILLION)
  • TABLE 85 NORTH AMERICA: CRISPR SERVICES MARKET FOR GRNA SYNTHESIS & CELL LINE DEVELOPMENT, BY COUNTRY, 2023-2031 (USD MILLION)
  • TABLE 86 EUROPE: CRISPR SERVICES MARKET FOR GRNA SYNTHESIS & CELL LINE DEVELOPMENT, BY COUNTRY, 2023-2031 (USD MILLION)
  • TABLE 87 ASIA PACIFIC: CRISPR SERVICES MARKET FOR GRNA SYNTHESIS & CELL LINE DEVELOPMENT, BY COUNTRY, 2023-2031 (USD MILLION)
  • TABLE 88 LATIN AMERICA: CRISPR SERVICES MARKET FOR GRNA SYNTHESIS & CELL LINE DEVELOPMENT, BY COUNTRY, 2023-2031 (USD MILLION)
  • TABLE 89 MIDDLE EAST: CRISPR SERVICES MARKET FOR GRNA SYNTHESIS & CELL LINE DEVELOPMENT, BY REGION, 2023-2031 (USD MILLION)
  • TABLE 90 GCC COUNTRIES: CRISPR SERVICES MARKET FOR GRNA SYNTHESIS & CELL LINE DEVELOPMENT, BY COUNTRY, 2023-2031 (USD MILLION)
  • TABLE 91 CRISPR SERVICES MARKET FOR SCREENING & VALIDATION, BY REGION, 2023-2031 (USD MILLION)
  • TABLE 92 NORTH AMERICA: CRISPR SERVICES MARKET FOR SCREENING & VALIDATION, BY COUNTRY, 2023-2031 (USD MILLION)
  • TABLE 93 EUROPE: CRISPR SERVICES MARKET FOR SCREENING & VALIDATION, BY COUNTRY, 2023-2031 (USD MILLION)
  • TABLE 94 ASIA PACIFIC: CRISPR SERVICES MARKET FOR SCREENING & VALIDATION, BY COUNTRY, 2023-2031 (USD MILLION)
  • TABLE 95 LATIN AMERICA: CRISPR SERVICES MARKET FOR SCREENING & VALIDATION, BY COUNTRY, 2023-2031 (USD MILLION)
  • TABLE 96 MIDDLE EAST: CRISPR SERVICES MARKET FOR SCREENING & VALIDATION, BY REGION, 2023-2031 (USD MILLION)
  • TABLE 97 GCC COUNTRIES: CRISPR SERVICES MARKET FOR SCREENING & VALIDATION, BY COUNTRY, 2023-2031 (USD MILLION)
  • TABLE 98 OTHER CRISPR SERVICES MARKET, BY REGION, 2023-2031 (USD MILLION)
  • TABLE 99 NORTH AMERICA: OTHER CRISPR SERVICES MARKET, BY COUNTRY, 2023-2031 (USD MILLION)
  • TABLE 100 EUROPE: OTHER CRISPR SERVICES MARKET, BY COUNTRY, 2023-2031 (USD MILLION)
  • TABLE 101 ASIA PACIFIC: OTHER CRISPR SERVICES MARKET, BY COUNTRY, 2023-2031 (USD MILLION)
  • TABLE 102 LATIN AMERICA: OTHER CRISPR SERVICES MARKET, BY COUNTRY, 2023-2031 (USD MILLION)
  • TABLE 103 MIDDLE EAST: OTHER CRISPR SERVICES MARKET, BY REGION, 2023-2031 (USD MILLION)
  • TABLE 104 GCC COUNTRIES: OTHER CRISPR SERVICES MARKET, BY COUNTRY, 2023-2031 (USD MILLION)
  • TABLE 105 CRISPR SERVICES MARKET, BY END USER, 2023-2031 (USD MILLION)
  • TABLE 106 CRISPR SERVICES MARKET FOR PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES, BY REGION, 2023-2031 (USD MILLION)
  • TABLE 107 NORTH AMERICA: CRISPR SERVICES MARKET FOR PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES, BY COUNTRY, 2023-2031 (USD MILLION)
  • TABLE 108 EUROPE: CRISPR SERVICES MARKET FOR PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES, BY COUNTRY, 2023-2031 (USD MILLION)
  • TABLE 109 ASIA PACIFIC: CRISPR SERVICES MARKET FOR PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES, BY COUNTRY, 2023-2031 (USD MILLION)
  • TABLE 110 LATIN AMERICA: CRISPR SERVICES MARKET FOR PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES, BY COUNTRY, 2023-2031 (USD MILLION)
  • TABLE 111 MIDDLE EAST: CRISPR SERVICES MARKET FOR PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES, BY REGION, 2023-2031 (USD MILLION)
  • TABLE 112 GCC COUNTRIES: CRISPR SERVICES MARKET FOR PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES, BY COUNTRY, 2023-2031 (USD MILLION)
  • TABLE 113 CRISPR SERVICES MARKET FOR ACADEMIC & RESEARCH INSTITUTES, BY REGION, 2023-2031 (USD MILLION)
  • TABLE 114 NORTH AMERICA: CRISPR SERVICES MARKET FOR ACADEMIC & RESEARCH INSTITUTES, BY COUNTRY, 2023-2031 (USD MILLION)
  • TABLE 115 EUROPE: CRISPR SERVICES MARKET FOR ACADEMIC & RESEARCH INSTITUTES, BY COUNTRY, 2023-2031 (USD MILLION)
  • TABLE 116 ASIA PACIFIC: CRISPR SERVICES MARKET FOR ACADEMIC & RESEARCH INSTITUTES, BY COUNTRY, 2023-2031 (USD MILLION)
  • TABLE 117 LATIN AMERICA: CRISPR SERVICES MARKET FOR ACADEMIC & RESEARCH INSTITUTES, BY COUNTRY, 2023-2031 (USD MILLION)
  • TABLE 118 MIDDLE EAST: CRISPR SERVICES MARKET FOR ACADEMIC & RESEARCH INSTITUTES, BY REGION, 2023-2031 (USD MILLION)
  • TABLE 119 GCC COUNTRIES: CRISPR SERVICES MARKET FOR ACADEMIC & RESEARCH INSTITUTES, BY COUNTRY, 2023-2031 (USD MILLION)
  • TABLE 120 CRISPR SERVICES MARKET FOR OTHER END USERS, BY REGION, 2023-2031 (USD MILLION)
  • TABLE 121 NORTH AMERICA: CRISPR SERVICES MARKET FOR OTHER END USERS, BY COUNTRY, 2023-2031 (USD MILLION)
  • TABLE 122 EUROPE: CRISPR SERVICES MARKET FOR OTHER END USERS, BY COUNTRY, 2023-2031 (USD MILLION)
  • TABLE 123 ASIA PACIFIC: CRISPR SERVICES MARKET FOR OTHER END USERS, BY COUNTRY, 2023-2031 (USD MILLION)
  • TABLE 124 LATIN AMERICA: CRISPR SERVICES MARKET FOR OTHER END USERS, BY COUNTRY, 2023-2031 (USD MILLION)
  • TABLE 125 MIDDLE EAST: CRISPR SERVICES MARKET FOR OTHER END USERS, BY REGION, 2023-2031 (USD MILLION)
  • TABLE 126 GCC COUNTRIES: CRISPR SERVICES MARKET FOR OTHER END USERS, BY COUNTRY, 2023-2031 (USD MILLION)
  • TABLE 127 CRISPR MARKET, BY APPLICATION, 2023-2031 (USD MILLION)
  • TABLE 128 CRISPR MARKET FOR DRUG DISCOVERY & DEVELOPMENT APPLICATIONS, BY REGION, 2023-2031 (USD MILLION)
  • TABLE 129 NORTH AMERICA: CRISPR MARKET FOR DRUG DISCOVERY & DEVELOPMENT APPLICATIONS, BY COUNTRY, 2023-2031 (USD MILLION)
  • TABLE 130 EUROPE: CRISPR MARKET FOR DRUG DISCOVERY & DEVELOPMENT APPLICATIONS, BY COUNTRY, 2023-2031 (USD MILLION)
  • TABLE 131 ASIA PACIFIC: CRISPR MARKET FOR DRUG DISCOVERY & DEVELOPMENT APPLICATIONS, BY COUNTRY, 2023-2031 (USD MILLION)
  • TABLE 132 LATIN AMERICA: CRISPR MARKET FOR DRUG DISCOVERY & DEVELOPMENT APPLICATIONS, BY COUNTRY, 2023-2031 (USD MILLION)
  • TABLE 133 MIDDLE EAST: CRISPR MARKET FOR DRUG DISCOVERY & DEVELOPMENT APPLICATIONS, BY REGION, 2023-2031 (USD MILLION)
  • TABLE 134 GCC COUNTRIES: CRISPR MARKET FOR DRUG DISCOVERY & DEVELOPMENT APPLICATIONS, BY COUNTRY, 2023-2031 (USD MILLION)
  • TABLE 135 CRISPR MARKET FOR AGRICULTURAL APPLICATIONS, BY REGION, 2023-2031 (USD MILLION)
  • TABLE 136 NORTH AMERICA: CRISPR MARKET FOR AGRICULTURAL APPLICATIONS, BY COUNTRY, 2023-2031 (USD MILLION)
  • TABLE 137 EUROPE: CRISPR MARKET FOR AGRICULTURAL APPLICATIONS, BY COUNTRY, 2023-2031 (USD MILLION)
  • TABLE 138 ASIA PACIFIC: CRISPR MARKET FOR AGRICULTURAL APPLICATIONS, BY COUNTRY, 2023-2031 (USD MILLION)
  • TABLE 139 LATIN AMERICA: CRISPR MARKET FOR AGRICULTURAL APPLICATIONS, BY COUNTRY, 2023-2031 (USD MILLION)
  • TABLE 140 MIDDLE EAST: CRISPR MARKET FOR AGRICULTURAL APPLICATIONS, BY REGION, 2023-2031 (USD MILLION)
  • TABLE 141 GCC COUNTRIES: CRISPR MARKET FOR AGRICULTURAL APPLICATIONS, BY COUNTRY, 2023-2031 (USD MILLION)
  • TABLE 142 CRISPR MARKET FOR OTHER APPLICATIONS, BY REGION, 2023-2031 (USD MILLION)
  • TABLE 143 NORTH AMERICA: CRISPR MARKET FOR OTHER APPLICATIONS, BY COUNTRY, 2023-2031 (USD MILLION)
  • TABLE 144 EUROPE: CRISPR MARKET FOR OTHER APPLICATIONS, BY COUNTRY, 2023-2031 (USD MILLION)
  • TABLE 145 ASIA PACIFIC: CRISPR MARKET FOR OTHER APPLICATIONS, BY COUNTRY, 2023-2031 (USD MILLION)
  • TABLE 146 LATIN AMERICA: CRISPR MARKET FOR OTHER APPLICATIONS, BY COUNTRY, 2023-2031 (USD MILLION)
  • TABLE 147 MIDDLE EAST: CRISPR MARKET FOR OTHER APPLICATIONS, BY REGION, 2023-2031 (USD MILLION)
  • TABLE 148 GCC COUNTRIES: CRISPR MARKET FOR OTHER APPLICATIONS, BY COUNTRY, 2023-2031 (USD MILLION)
  • TABLE 149 CRISPR MARKET, BY REGION, 2023-2031 (USD MILLION)
  • TABLE 150 NORTH AMERICA: CRISPR MARKET, BY OFFERING, 2023-2031 (USD MILLION)
  • TABLE 151 NORTH AMERICA: CRISPR MARKET, BY PRODUCT, 2023-2031 (USD MILLION)
  • TABLE 152 NORTH AMERICA: CRISPR PRODUCTS MARKET, BY END USER, 2023-2031 (USD MILLION)
  • TABLE 153 NORTH AMERICA: CRISPR MARKET, BY SERVICE, 2023-2031 (USD MILLION)
  • TABLE 154 NORTH AMERICA: CRISPR MARKET, BY APPLICATION, 2023-2031 (USD MILLION)
  • TABLE 155 NORTH AMERICA: CRISPR SERVICES MARKET, BY END USER, 2023-2031 (USD MILLION)
  • TABLE 156 US: CRISPR MARKET, BY OFFERING, 2023-2031 (USD MILLION)
  • TABLE 157 US: CRISPR MARKET, BY PRODUCT, 2023-2031 (USD MILLION)
  • TABLE 158 US: CRISPR PRODUCTS MARKET, BY END USER, 2023-2031 (USD MILLION)
  • TABLE 159 US: CRISPR MARKET, BY SERVICE, 2023-2031 (USD MILLION)
  • TABLE 160 US: CRISPR MARKET, BY APPLICATION, 2023-2031 (USD MILLION)
  • TABLE 161 US: CRISPR SERVICES MARKET, BY END USER, 2023-2031 (USD MILLION)
  • TABLE 162 CANADA: CRISPR MARKET, BY OFFERING, 2023-2031 (USD MILLION)
  • TABLE 163 CANADA: CRISPR MARKET, BY PRODUCT, 2023-2031 (USD MILLION)
  • TABLE 164 CANADA: CRISPR PRODUCTS MARKET, BY END USER, 2023-2031 (USD MILLION)
  • TABLE 165 CANADA: CRISPR MARKET, BY SERVICE, 2023-2031 (USD MILLION)
  • TABLE 166 CANADA: CRISPR MARKET, BY APPLICATION, 2023-2031 (USD MILLION)
  • TABLE 167 CANADA: CRISPR SERVICES MARKET, BY END USER, 2023-2031 (USD MILLION)
  • TABLE 168 EUROPE: CRISPR MARKET, BY COUNTRY, 2023-2031 (USD MILLION)
  • TABLE 169 EUROPE: CRISPR MARKET, BY OFFERING, 2023-2031 (USD MILLION)
  • TABLE 170 EUROPE: CRISPR MARKET, BY PRODUCT, 2023-2031 (USD MILLION)
  • TABLE 171 EUROPE: CRISPR PRODUCTS MARKET, BY END USER, 2023-2031 (USD MILLION)
  • TABLE 172 EUROPE: CRISPR MARKET, BY SERVICE, 2023-2031 (USD MILLION)
  • TABLE 173 EUROPE: CRISPR MARKET, BY APPLICATION, 2023-2031 (USD MILLION)
  • TABLE 174 EUROPE: CRISPR SERVICES MARKET, BY END USER, 2023-2031 (USD MILLION)
  • TABLE 175 GERMANY: CRISPR MARKET, BY OFFERING, 2023-2031 (USD MILLION)
  • TABLE 176 GERMANY: CRISPR MARKET, BY PRODUCT, 2023-2031 (USD MILLION)
  • TABLE 177 GERMANY: CRISPR PRODUCTS MARKET, BY END USER, 2023-2031 (USD MILLION)
  • TABLE 178 GERMANY: CRISPR MARKET, BY SERVICE, 2023-2031 (USD MILLION)
  • TABLE 179 GERMANY: CRISPR MARKET, BY APPLICATION, 2023-2031 (USD MILLION)
  • TABLE 180 GERMANY: CRISPR SERVICES MARKET, BY END USER, 2023-2031 (USD MILLION)
  • TABLE 181 UK: CRISPR MARKET, BY OFFERING, 2023-2031 (USD MILLION)
  • TABLE 182 UK: CRISPR MARKET, BY PRODUCT, 2023-2031 (USD MILLION)
  • TABLE 183 UK: CRISPR PRODUCTS MARKET, BY END USER, 2023-2031 (USD MILLION)
  • TABLE 184 UK: CRISPR MARKET, BY SERVICE, 2023-2031 (USD MILLION)
  • TABLE 185 UK: CRISPR MARKET, BY APPLICATION, 2023-2031 (USD MILLION)
  • TABLE 186 UK: CRISPR SERVICES MARKET, BY END USER, 2023-2031 (USD MILLION)
  • TABLE 187 FRANCE: CRISPR MARKET, BY OFFERING, 2023-2031 (USD MILLION)
  • TABLE 188 FRANCE: CRISPR MARKET, BY PRODUCT, 2023-2031 (USD MILLION)
  • TABLE 189 FRANCE: CRISPR PRODUCTS MARKET, BY END USER, 2023-2031 (USD MILLION)
  • TABLE 190 FRANCE: CRISPR MARKET, BY SERVICE, 2023-2031 (USD MILLION)
  • TABLE 191 FRANCE: CRISPR MARKET, BY APPLICATION, 2023-2031 (USD MILLION)
  • TABLE 192 FRANCE: CRISPR SERVICES MARKET, BY END USER, 2023-2031 (USD MILLION)
  • TABLE 193 ITALY: CRISPR MARKET, BY OFFERING, 2023-2031 (USD MILLION)
  • TABLE 194 ITALY: CRISPR MARKET, BY PRODUCT, 2023-2031 (USD MILLION)
  • TABLE 195 ITALY: CRISPR PRODUCTS MARKET, BY END USER, 2023-2031 (USD MILLION)
  • TABLE 196 ITALY: CRISPR MARKET, BY SERVICE, 2023-2031 (USD MILLION)
  • TABLE 197 ITALY: CRISPR MARKET, BY APPLICATION, 2023-2031 (USD MILLION)
  • TABLE 198 ITALY: CRISPR SERVICES MARKET, BY END USER, 2023-2031 (USD MILLION)
  • TABLE 199 SPAIN: CRISPR MARKET, BY OFFERING, 2023-2031 (USD MILLION)
  • TABLE 200 SPAIN: CRISPR MARKET, BY PRODUCT, 2023-2031 (USD MILLION)
  • TABLE 201 SPAIN: CRISPR PRODUCTS MARKET, BY END USER, 2023-2031 (USD MILLION)
  • TABLE 202 SPAIN: CRISPR MARKET, BY SERVICE, 2023-2031 (USD MILLION)
  • TABLE 203 SPAIN: CRISPR MARKET, BY APPLICATION, 2023-2031 (USD MILLION)
  • TABLE 204 SPAIN: CRISPR SERVICES MARKET, BY END USER, 2023-2031 (USD MILLION)
  • TABLE 205 REST OF EUROPE: CRISPR MARKET, BY OFFERING, 2023-2031 (USD MILLION)
  • TABLE 206 REST OF EUROPE: CRISPR MARKET, BY PRODUCT, 2023-2031 (USD MILLION)
  • TABLE 207 REST OF EUROPE: CRISPR MARKET, BY SERVICE, 2023-2031 (USD MILLION)
  • TABLE 208 REST OF EUROPE: CRISPR PRODUCTS MARKET, BY END USER, 2023-2031 (USD MILLION)
  • TABLE 209 REST OF EUROPE: CRISPR MARKET, BY APPLICATION, 2023-2031 (USD MILLION)
  • TABLE 210 REST OF EUROPE: CRISPR SERVICES MARKET, BY END USER, 2023-2031 (USD MILLION)
  • TABLE 211 ASIA PACIFIC: CRISPR MARKET, BY COUNTRY, 2023-2031 (USD MILLION)
  • TABLE 212 ASIA PACIFIC: CRISPR MARKET, BY OFFERING, 2023-2031 (USD MILLION)
  • TABLE 213 ASIA PACIFIC: CRISPR MARKET, BY PRODUCT, 2023-2031 (USD MILLION)
  • TABLE 214 ASIA PACIFIC: CRISPR PRODUCTS MARKET, BY END USER, 2023-2031 (USD MILLION)
  • TABLE 215 ASIA PACIFIC: CRISPR MARKET, BY SERVICE, 2023-2031 (USD MILLION)
  • TABLE 216 ASIA PACIFIC: CRISPR MARKET, BY APPLICATION, 2023-2031 (USD MILLION)
  • TABLE 217 ASIA PACIFIC: CRISPR SERVICES MARKET, BY END USER, 2023-2031 (USD MILLION)
  • TABLE 218 CHINA: CRISPR MARKET, BY OFFERING, 2023-2031 (USD MILLION)
  • TABLE 219 CHINA: CRISPR MARKET, BY PRODUCT, 2023-2031 (USD MILLION)
  • TABLE 220 CHINA: CRISPR PRODUCTS MARKET, BY END USER, 2023-2031 (USD MILLION)
  • TABLE 221 CHINA: CRISPR MARKET, BY SERVICE, 2023-2031 (USD MILLION)
  • TABLE 222 CHINA: CRISPR MARKET, BY APPLICATION, 2023-2031 (USD MILLION)
  • TABLE 223 CHINA: CRISPR SERVICES MARKET, BY END USER, 2023-2031 (USD MILLION)
  • TABLE 224 JAPAN: CRISPR MARKET, BY OFFERING, 2023-2031 (USD MILLION)
  • TABLE 225 JAPAN: CRISPR MARKET, BY PRODUCT, 2023-2031 (USD MILLION)
  • TABLE 226 JAPAN: CRISPR PRODUCTS MARKET, BY END USER, 2023-2031 (USD MILLION)
  • TABLE 227 JAPAN: CRISPR MARKET, BY SERVICE, 2023-2031 (USD MILLION)
  • TABLE 228 JAPAN: CRISPR MARKET, BY APPLICATION, 2023-2031 (USD MILLION)
  • TABLE 229 JAPAN: CRISPR SERVICES MARKET, BY END USER, 2023-2031 (USD MILLION)
  • TABLE 230 INDIA: CRISPR MARKET, BY OFFERING, 2023-2031 (USD MILLION)
  • TABLE 231 INDIA: CRISPR MARKET, BY PRODUCT, 2023-2031 (USD MILLION)
  • TABLE 232 INDIA: CRISPR PRODUCTS MARKET, BY END USER, 2023-2031 (USD MILLION)
  • TABLE 233 INDIA: CRISPR MARKET, BY SERVICE, 2023-2031 (USD MILLION)
  • TABLE 234 INDIA: CRISPR MARKET, BY APPLICATION, 2023-2031 (USD MILLION)
  • TABLE 235 INDIA: CRISPR SERVICES MARKET, BY END USER, 2023-2031 (USD MILLION)
  • TABLE 236 AUSTRALIA: CRISPR MARKET, BY OFFERING, 2023-2031 (USD MILLION)
  • TABLE 237 AUSTRALIA: CRISPR MARKET, BY PRODUCT, 2023-2031 (USD MILLION)
  • TABLE 238 AUSTRALIA: CRISPR PRODUCTS MARKET, BY END USER, 2023-2031 (USD MILLION)
  • TABLE 239 AUSTRALIA: CRISPR MARKET, BY SERVICE, 2023-2031 (USD MILLION)
  • TABLE 240 AUSTRALIA: CRISPR MARKET, BY APPLICATION, 2023-2031 (USD MILLION)
  • TABLE 241 AUSTRALIA: CRISPR SERVICES MARKET, BY END USER, 2023-2031 (USD MILLION)
  • TABLE 242 SOUTH KOREA: CRISPR MARKET, BY OFFERING, 2023-2031 (USD MILLION)
  • TABLE 243 SOUTH KOREA: CRISPR MARKET, BY PRODUCT, 2023-2031 (USD MILLION)
  • TABLE 244 SOUTH KOREA: CRISPR PRODUCTS MARKET, BY END USER, 2023-2031 (USD MILLION)
  • TABLE 245 SOUTH KOREA: CRISPR MARKET, BY SERVICE, 2023-2031 (USD MILLION)
  • TABLE 246 SOUTH KOREA: CRISPR MARKET, BY APPLICATION, 2023-2031 (USD MILLION)
  • TABLE 247 SOUTH KOREA: CRISPR SERVICES MARKET, BY END USER, 2023-2031 (USD MILLION)
  • TABLE 248 REST OF ASIA PACIFIC: CRISPR MARKET, BY OFFERING, 2023-2031 (USD MILLION)
  • TABLE 249 REST OF ASIA PACIFIC: CRISPR MARKET, BY PRODUCT, 2023-2031 (USD MILLION)
  • TABLE 250 REST OF ASIA PACIFIC: CRISPR PRODUCTS MARKET, BY END USER, 2023-2031 (USD MILLION)
  • TABLE 251 REST OF ASIA PACIFIC: CRISPR MARKET, BY SERVICE, 2023-2031 (USD MILLION)
  • TABLE 252 REST OF ASIA PACIFIC: CRISPR MARKET, BY APPLICATION, 2023-2031 (USD MILLION)
  • TABLE 253 REST OF ASIA PACIFIC: CRISPR SERVICES MARKET, BY END USER, 2023-2031 (USD MILLION)
  • TABLE 254 LATIN AMERICA: CRISPR MARKET, BY COUNTRY, 2023-2031 (USD MILLION)
  • TABLE 255 LATIN AMERICA: CRISPR MARKET, BY OFFERING, 2023-2031 (USD MILLION)
  • TABLE 256 LATIN AMERICA: CRISPR MARKET, BY PRODUCT, 2023-2031 (USD MILLION)
  • TABLE 257 LATIN AMERICA: CRISPR PRODUCTS MARKET, BY END USER, 2023-2031 (USD MILLION)
  • TABLE 258 LATIN AMERICA: CRISPR MARKET, BY SERVICE, 2023-2031 (USD MILLION)
  • TABLE 259 LATIN AMERICA: CRISPR MARKET, BY APPLICATION, 2023-2031 (USD MILLION)
  • TABLE 260 LATIN AMERICA: CRISPR SERVICES MARKET, BY END USER, 2023-2031 (USD MILLION)
  • TABLE 261 BRAZIL: CRISPR MARKET, BY OFFERING, 2023-2031 (USD MILLION)
  • TABLE 262 BRAZIL: CRISPR MARKET, BY PRODUCT, 2023-2031 (USD MILLION)
  • TABLE 263 BRAZIL: CRISPR PRODUCTS MARKET, BY END USER, 2023-2031 (USD MILLION)
  • TABLE 264 BRAZIL: CRISPR MARKET, BY SERVICE, 2023-2031 (USD MILLION)
  • TABLE 265 BRAZIL: CRISPR MARKET, BY APPLICATION, 2023-2031 (USD MILLION)
  • TABLE 266 BRAZIL: CRISPR SERVICES MARKET, BY END USER, 2023-2031 (USD MILLION)
  • TABLE 267 REST OF LATIN AMERICA: CRISPR MARKET, BY OFFERING, 2023-2031 (USD MILLION)
  • TABLE 268 REST OF LATIN AMERICA: CRISPR MARKET, BY PRODUCT, 2023-2031 (USD MILLION)
  • TABLE 269 REST OF LATIN AMERICA: CRISPR PRODUCTS MARKET, BY END USER, 2023-2031 (USD MILLION)
  • TABLE 270 REST OF LATIN AMERICA: CRISPR MARKET, BY SERVICE, 2023-2031 (USD MILLION)
  • TABLE 271 REST OF LATIN AMERICA: CRISPR MARKET, BY APPLICATION, 2023-2031 (USD MILLION)
  • TABLE 272 REST OF LATIN AMERICA: CRISPR SERVICES MARKET, BY END USER, 2023-2031 (USD MILLION)
  • TABLE 273 MIDDLE EAST: CRISPR MARKET, BY REGION, 2023-2031 (USD MILLION)
  • TABLE 274 MIDDLE EAST: CRISPR MARKET, BY OFFERING, 2023-2031 (USD MILLION)
  • TABLE 275 MIDDLE EAST: CRISPR MARKET, BY PRODUCT, 2023-2031 (USD MILLION)
  • TABLE 276 MIDDLE EAST: CRISPR PRODUCTS MARKET, BY END USER, 2023-2031 (USD MILLION)
  • TABLE 277 MIDDLE EAST: CRISPR MARKET, BY SERVICE, 2023-2031 (USD MILLION)
  • TABLE 278 MIDDLE EAST: CRISPR MARKET, BY APPLICATION, 2023-2031 (USD MILLION)
  • TABLE 279 MIDDLE EAST: CRISPR SERVICES MARKET, BY END USER, 2023-2031 (USD MILLION)
  • TABLE 280 GCC COUNTRIES: CRISPR MARKET, BY COUNTRY, 2023-2031 (USD MILLION)
  • TABLE 281 GCC COUNTRIES: CRISPR MARKET, BY OFFERING, 2023-2031 (USD MILLION)
  • TABLE 282 GCC COUNTRIES: CRISPR MARKET, BY PRODUCT, 2023-2031 (USD MILLION)
  • TABLE 283 GCC COUNTRIES: CRISPR PRODUCTS MARKET, BY END USER, 2023-2031 (USD MILLION)
  • TABLE 284 GCC COUNTRIES: CRISPR MARKET, BY SERVICE, 2023-2031 (USD MILLION)
  • TABLE 285 GCC COUNTRIES: CRISPR MARKET, BY APPLICATION, 2023-2031 (USD MILLION)
  • TABLE 286 GCC COUNTRIES: CRISPR SERVICES MARKET, BY END USER, 2023-2031 (USD MILLION)
  • TABLE 287 SAUDI ARABIA: CRISPR MARKET, BY OFFERING, 2023-2031 (USD MILLION)
  • TABLE 288 SAUDI ARABIA: CRISPR MARKET, BY PRODUCT, 2023-2031 (USD MILLION)
  • TABLE 289 SAUDI ARABIA: CRISPR PRODUCTS MARKET, BY END USER, 2023-2031 (USD MILLION)
  • TABLE 290 SAUDI ARABIA: CRISPR MARKET, BY SERVICE, 2023-2031 (USD MILLION)
  • TABLE 291 SAUDI ARABIA: CRISPR MARKET, BY APPLICATION, 2023-2031 (USD MILLION)
  • TABLE 292 SAUDI ARABIA: CRISPR SERVICES MARKET, BY END USER, 2023-2031 (USD MILLION)
  • TABLE 293 UAE: CRISPR MARKET, BY OFFERING, 2023-2031 (USD MILLION)
  • TABLE 294 UAE: CRISPR MARKET, BY PRODUCT, 2023-2031 (USD MILLION)
  • TABLE 295 UAE: CRISPR PRODUCTS MARKET, BY END USER, 2023-2031 (USD MILLION)
  • TABLE 296 UAE: CRISPR MARKET, BY SERVICE, 2023-2031 (USD MILLION)
  • TABLE 297 UAE: CRISPR MARKET, BY APPLICATION, 2023-2031 (USD MILLION)
  • TABLE 298 UAE: CRISPR SERVICES MARKET, BY END USER, 2023-2031 (USD MILLION)
  • TABLE 299 REST OF GCC COUNTRIES: CRISPR MARKET, BY OFFERING, 2023-2031 (USD MILLION)
  • TABLE 300 REST OF GCC COUNTRIES: CRISPR MARKET, BY PRODUCT, 2023-2031 (USD MILLION)
  • TABLE 301 REST OF GCC COUNTRIES: CRISPR PRODUCTS MARKET, BY END USER, 2023-2031 (USD MILLION)
  • TABLE 302 REST OF GCC COUNTRIES: CRISPR MARKET, BY SERVICE, 2023-2031 (USD MILLION)
  • TABLE 303 REST OF GCC COUNTRIES: CRISPR MARKET, BY APPLICATION, 2023-2031 (USD MILLION)
  • TABLE 304 REST OF GCC COUNTRIES: CRISPR SERVICES MARKET, BY END USER, 2023-2031 (USD MILLION)
  • TABLE 305 REST OF MIDDLE EAST: CRISPR MARKET, BY OFFERING, 2023-2031 (USD MILLION)
  • TABLE 306 REST OF MIDDLE EAST: CRISPR MARKET, BY PRODUCT, 2023-2031 (USD MILLION)
  • TABLE 307 REST OF MIDDLE EAST: CRISPR PRODUCTS MARKET, BY END USER, 2023-2031 (USD MILLION)
  • TABLE 308 REST OF MIDDLE EAST: CRISPR MARKET, BY SERVICE, 2023-2031 (USD MILLION)
  • TABLE 309 REST OF MIDDLE EAST: CRISPR MARKET, BY APPLICATION, 2023-2031 (USD MILLION)
  • TABLE 310 REST OF MIDDLE EAST: CRISPR SERVICES MARKET, BY END USER, 2023-2031 (USD MILLION)
  • TABLE 311 AFRICA: CRISPR MARKET, BY OFFERING, 2023-2031 (USD MILLION)
  • TABLE 312 AFRICA: CRISPR MARKET, BY PRODUCT, 2023-2031 (USD MILLION)
  • TABLE 313 AFRICA: CRISPR PRODUCTS MARKET, BY END USER, 2023-2031 (USD MILLION)
  • TABLE 314 AFRICA: CRISPR MARKET, BY SERVICE, 2023-2031 (USD MILLION)
  • TABLE 315 AFRICA: CRISPR MARKET, BY APPLICATION, 2023-2031 (USD MILLION)
  • TABLE 316 AFRICA: CRISPR SERVICES MARKET, BY END USER, 2023-2031 (USD MILLION)
  • TABLE 317 STRATEGIES ADOPTED BY KEY PLAYERS IN CRISPR MARKET, JANUARY 2023-SEPTEMBER 2026
  • TABLE 318 CRISPR MARKET: DEGREE OF COMPETITION
  • TABLE 319 CRISPR MARKET: REGION FOOTPRINT
  • TABLE 320 CRISPR MARKET: PRODUCT FOOTPRINT
  • TABLE 321 CRISPR MARKET: SERVICE FOOTPRINT
  • TABLE 322 CRISPR MARKET: APPLICATION FOOTPRINT
  • TABLE 323 CRISPR MARKET: DETAILED LIST OF KEY STARTUPS/SMES
  • TABLE 324 CRISPR MARKET: COMPETITIVE BENCHMARKING OF KEY STARTUPS/SMES
  • TABLE 325 CRISPR MARKET: PRODUCT LAUNCHES, JANUARY 2023-SEPTEMBER 2026
  • TABLE 326 CRISPR MARKET: DEALS, JANUARY 2023-SEPTEMBER 2026
  • TABLE 327 CRISPR MARKET: EXPANSIONS, JANUARY 2023-SEPTEMBER 2026
  • TABLE 328 THERMO FISHER SCIENTIFIC INC.: COMPANY OVERVIEW
  • TABLE 329 THERMO FISHER SCIENTIFIC INC.: PRODUCTS & SERVICES OFFERED
  • TABLE 330 THERMO FISHER SCIENTIFIC INC.: EXPANSIONS, JANUARY 2023-SEPTEMBER 2026
  • TABLE 331 MERCK KGAA: COMPANY OVERVIEW
  • TABLE 332 MERCK KGAA: PRODUCTS & SERVICES OFFERED
  • TABLE 333 MERCK KGAA: PRODUCT LAUNCHES, JANUARY 2023-SEPTEMBER 2026
  • TABLE 334 MERCK KGAA: DEALS, JANUARY 2023-SEPTEMBER 2026
  • TABLE 335 AGILENT TECHNOLOGIES, INC.: COMPANY OVERVIEW
  • TABLE 336 AGILENT TECHNOLOGIES, INC.: PRODUCTS & SERVICES OFFERED
  • TABLE 337 AGILENT TECHNOLOGIES, INC.: DEALS, JANUARY 2023-SEPTEMBER 2026
  • TABLE 338 AGILENT TECHNOLOGIES, INC.: EXPANSIONS, JANUARY 2023-SEPTEMBER 2026
  • TABLE 339 GENSCRIPT: COMPANY OVERVIEW
  • TABLE 340 GENSCRIPT: PRODUCTS & SERVICES OFFERED
  • TABLE 341 GENSCRIPT: DEALS, JANUARY 2023-SEPTEMBER 2026
  • TABLE 342 GENSCRIPT: EXPANSIONS, JANUARY 2023-SEPTEMBER 2026
  • TABLE 343 REVVITY: COMPANY OVERVIEW
  • TABLE 344 REVVITY: PRODUCTS & SERVICES OFFERED
  • TABLE 345 REVVITY: PRODUCT LAUNCHES, JANUARY 2023-SEPTEMBER 2026
  • TABLE 346 REVVITY: DEALS, JANUARY 2023-SEPTEMBER 2026
  • TABLE 347 LONZA: COMPANY OVERVIEW
  • TABLE 348 LONZA: PRODUCTS & SERVICES OFFERED
  • TABLE 349 LONZA: PRODUCT LAUNCHES, JANUARY 2023-SEPTEMBER 2026
  • TABLE 350 LONZA: DEALS, JANUARY 2023-SEPTEMBER 2026
  • TABLE 351 LONZA: EXPANSIONS, JANUARY 2023-SEPTEMBER 2026
  • TABLE 352 DANAHER CORPORATION: COMPANY OVERVIEW
  • TABLE 353 DANAHER CORPORATION: PRODUCTS & SERVICES OFFERED
  • TABLE 354 DANAHER CORPORATION: PRODUCT LAUNCHES, JANUARY 2023-SEPTEMBER 2026
  • TABLE 355 DANAHER CORPORATION: DEALS, JANUARY 2023-SEPTEMBER 2026
  • TABLE 356 TAKARA BIO INC.: COMPANY OVERVIEW
  • TABLE 357 TAKARA BIO INC.: PRODUCTS & SERVICES OFFERED
  • TABLE 358 TAKARA BIO INC.: DEALS, JANUARY 2023-SEPTEMBER 2026
  • TABLE 359 CREATIVE BIOGENE: COMPANY OVERVIEW
  • TABLE 360 CREATIVE BIOGENE: PRODUCTS & SERVICES OFFERED
  • TABLE 361 CREATIVE BIOGENE: SERVICE LAUNCHES, JANUARY 2023-SEPTEMBER 2026
  • TABLE 362 FUJIAN SUNYBIOTECH CO., LTD.: COMPANY OVERVIEW
  • TABLE 363 FUJIAN SUNYBIOTECH CO., LTD.: PRODUCTS & SERVICES OFFERED
  • TABLE 364 EDITCO: COMPANY OVERVIEW
  • TABLE 365 EDITCO: PRODUCTS & SERVICES OFFERED
  • TABLE 366 EDITCO: DEALS, JANUARY 2023-SEPTEMBER 2026
  • TABLE 367 CARIBOU BIOSCIENCES, INC.: COMPANY OVERVIEW
  • TABLE 368 CARIBOU BIOSCIENCES, INC.: PRODUCTS & SERVICES OFFERED
  • TABLE 369 CARIBOU BIOSCIENCES, INC.: DEALS, JANUARY 2023-SEPTEMBER 2026
  • TABLE 370 DEMEETRA AGBIO: COMPANY OVERVIEW
  • TABLE 371 DEMEETRA AGBIO: PRODUCTS & SERVICES OFFERED
  • TABLE 372 DEMEETRA AGBIO: DEALS, JANUARY 2023-SEPTEMBER 2026
  • TABLE 373 ORIGENE TECHNOLOGIES, INC.: COMPANY OVERVIEW
  • TABLE 374 ORIGENE TECHNOLOGIES, INC.: PRODUCTS & SERVICES OFFERED
  • TABLE 375 CELLECTA, INC.: COMPANY OVERVIEW
  • TABLE 376 CELLECTA, INC.: PRODUCTS & SERVICES OFFERED
  • TABLE 377 MAMMOTH BIOSCIENCES, INC.: COMPANY OVERVIEW
  • TABLE 378 APPLIED STEMCELL: COMPANY OVERVIEW
  • TABLE 379 NEW ENGLAND BIOLABS: COMPANY OVERVIEW
  • TABLE 380 TOOLGEN, INC.: COMPANY OVERVIEW
  • TABLE 381 GENECOPOEIA, INC.: COMPANY OVERVIEW
  • TABLE 382 TWIST BIOSCIENCE: COMPANY OVERVIEW
  • TABLE 383 SYNTHEGO: COMPANY OVERVIEW
  • TABLE 384 EGENESIS: COMPANY OVERVIEW
  • TABLE 385 MANUS BIO: COMPANY OVERVIEW
  • TABLE 386 PRECISION BIOSCIENCES: COMPANY OVERVIEW
  • TABLE 387 IMPACT ANALYSIS OF SUPPLY-SIDE AND DEMAND-SIDE FACTORS
  • TABLE 388 CRISPR MARKET: RISK ANALYSIS

List of Figures

  • FIGURE 1 CRISPR MARKET SEGMENTATION & REGIONAL SCOPE
  • FIGURE 2 MARKET SCENARIO
  • FIGURE 3 GLOBAL CRISPR MARKET, 2023-2031
  • FIGURE 4 MAJOR STRATEGIES ADOPTED BY KEY PLAYERS IN CRISPR MARKET, 2023-2026
  • FIGURE 5 DISRUPTIONS INFLUENCING GROWTH OF CRISPR MARKET
  • FIGURE 6 HIGH-GROWTH SEGMENTS IN CRISPR MARKET, 2026-2031
  • FIGURE 7 ASIA PACIFIC TO REGISTER HIGHEST CAGR IN CRISPR MARKET, IN TERMS OF VALUE, DURING FORECAST PERIOD
  • FIGURE 8 GROWING INVESTMENTS IN CRISPR TECHNOLOGY AND EXPANDING APPLICATIONS TO DRIVE MARKET GROWTH
  • FIGURE 9 PRODUCTS ACCOUNTED FOR LARGEST SHARE OF CRISPR MARKET IN NORTH AMERICA IN 2025
  • FIGURE 10 CHINA TO BE FASTEST-GROWING MARKET IN GLOBAL CRISPR MARKET DURING FORECAST PERIOD
  • FIGURE 11 PRODUCTS SEGMENT TO DOMINATE MARKET DURING FORECAST PERIOD
  • FIGURE 12 CRISPR MARKET: DRIVERS, RESTRAINTS, OPPORTUNITIES, AND CHALLENGES
  • FIGURE 13 TOP 10 LEADING CRISPR STARTUPS BASED ON INVESTMENTS RAISED IN 2024
  • FIGURE 14 CRISPR MARKET: PORTER'S FIVE FORCES ANALYSIS
  • FIGURE 15 CRISPR MARKET: VALUE CHAIN ANALYSIS
  • FIGURE 16 CRISPR MARKET: ECOSYSTEM ANALYSIS
  • FIGURE 17 AVERAGE SELLING PRICE OF CRISPR KITS & REAGENTS, BY KEY PLAYER (2025)
  • FIGURE 18 AVERAGE SELLING PRICE OF CRISPR KITS & REAGENTS, BY REGION, 2025 (USD)
  • FIGURE 19 CRISPR MARKET: TRENDS/DISRUPTIONS IMPACTING CUSTOMERS' BUSINESSES
  • FIGURE 20 INVESTMENT & FUNDING SCENARIO, 2023-2025 (USD MILLION)
  • FIGURE 21 PATENT APPLICATIONS IN CRISPR MARKET, JANUARY 2015-DECEMBER 2025
  • FIGURE 22 IMPACT OF AI/GEN AI ON CRISPR MARKET
  • FIGURE 23 INFLUENCE OF KEY STAKEHOLDERS ON BUYING PROCESS, BY OFFERING
  • FIGURE 24 KEY BUYING CRITERIA OF END USERS FOR CRISPR PRODUCTS
  • FIGURE 25 KEY SELECTION CRITERIA OF END USERS FOR CRISPR SERVICES
  • FIGURE 26 NORTH AMERICA: CRISPR MARKET SNAPSHOT
  • FIGURE 27 ASIA PACIFIC: CRISPR MARKET SNAPSHOT
  • FIGURE 28 REVENUE ANALYSIS OF KEY PLAYERS IN CRISPR MARKET, 2021-2025
  • FIGURE 29 MARKET SHARE ANALYSIS OF KEY PLAYERS IN CRISPR MARKET, 2025
  • FIGURE 30 CRISPR MARKET: COMPANY EVALUATION MATRIX (KEY PLAYERS), 2025
  • FIGURE 31 CRISPR MARKET: COMPANY FOOTPRINT
  • FIGURE 32 CRISPR MARKET: COMPANY EVALUATION MATRIX (STARTUPS/SMES), 2025
  • FIGURE 33 YEAR-TO-DATE (YTD) PRICE TOTAL RETURN AND 5-YEAR STOCK BETA OF KEY VENDORS
  • FIGURE 34 EV/EBITDA OF KEY VENDORS
  • FIGURE 35 CRISPR MARKET: BRAND COMPARISON
  • FIGURE 36 THERMO FISHER SCIENTIFIC INC.: COMPANY SNAPSHOT (2025)
  • FIGURE 37 MERCK KGAA: COMPANY SNAPSHOT (2025)
  • FIGURE 38 AGILENT TECHNOLOGIES, INC.: COMPANY SNAPSHOT (2025)
  • FIGURE 39 GENSCRIPT: COMPANY SNAPSHOT (2025)
  • FIGURE 40 REVVITY: COMPANY SNAPSHOT (2025)
  • FIGURE 41 LONZA: COMPANY SNAPSHOT (2025)
  • FIGURE 42 DANAHER CORPORATION: COMPANY SNAPSHOT (2025)
  • FIGURE 43 TAKARA BIO INC.: COMPANY SNAPSHOT (2024)
  • FIGURE 44 CARIBOU BIOSCIENCES, INC.: COMPANY SNAPSHOT (2025)
  • FIGURE 45 CRISPR MARKET: RESEARCH DESIGN
  • FIGURE 46 CRISPR MARKET: BREAKDOWN OF PRIMARY INTERVIEWS
  • FIGURE 47 CRISPR MARKET SIZE ESTIMATION (SUPPLY-SIDE ANALYSIS), 2025
  • FIGURE 48 CRISPR MARKET ESTIMATION: APPROACH 1 (COMPANY REVENUE ANALYSIS-BASED ESTIMATION), 2025
  • FIGURE 49 ILLUSTRATIVE EXAMPLE OF THERMO FISHER SCIENTIFIC INC.: REVENUE SHARE ANALYSIS (2025)
  • FIGURE 50 MARKET SIZE VALIDATION FROM PRIMARY SOURCES
  • FIGURE 51 SEGMENTAL MARKET SIZE ESTIMATION METHODOLOGY: TOP-DOWN APPROACH
  • FIGURE 52 CRISPR MARKET: CAGR PROJECTIONS
  • FIGURE 53 DATA TRIANGULATION METHODOLOGY